1 Porst H.Prostaglandin E 1 and nitric oxide donorlisidomine for erectile failure:a diagnostic comparitive study of 40 patients. J Urol,1993;149:1 280
2 Truss M C,Becker AJ,Schultheiss D,et al. Intracav ernous pharmaco the rapy. World J Urol,1997;15:7 1
3 Armstrong DK,Convery A,Dinsmore WW.Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J S td Aids,1993;4:214
4 Ballard SA,Gingell C J,Tang K,et al. Effects of sildenafil on the relaxation of human corpus cave rnosum tissue in vitro and on the activities of cyclic nucleotide phosphodieste rase is ozyme s.J Uro l,1998;1 59(6):2 164
5 Goldstein I,Lue TF,Padma-Nathan H,et al. Oral sildenafil in the treatment of erecfile dysfunction.New Engl J Med,1998;3 38(20):1397
6 Lue T F and the Sildenafil Study Group. A study of sildenafil (VIAGRA T M),a new oral agent for the treatment of male erectile dysfunction.J Uro l,1997;157(suppl):1 81
7 Jeremy JY,Ballard SA,Naylor AM,et al. Effects of sildenafil,a type-5 cGMP phosphodie sterase inhibitor,and papave rine on cyclic cGMP and cyclicAMP levels in the rabbit corpus cavernosum in vitro.Br J Urol,1997;79(19):958
8 Mor eland RB,Goldstein I,Traish A.Sildenafil,ano velinhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.Life Sci,1998;62(20):3 09
9 Burnett AL.Nitric oxide in the penis:physiology and pathology.J Uro l,1997;1 57:320
10 Pfizer Labs. VIAGRA TM (Sildenafil citrate). Report of Pfizer Labs,1998;March 11 Carter AJ,Ballard SA,Naylor AM. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil one rectile function in the anesthetized dog. J Urol,1998;160(1):242
12 Cooper JDH,Muirhead DC,Taylo r JE,et a l. Dev elopment of an assay for the simultaneous
13 determination of sildenafil (Via gr a) and its met abo lite (UK-103,320) using automated
14 sequential trace enrichment of dialy sates and high-per formance liquid chromato graphy.J Chroma togra B,1997;7 01:87
13 Rance DJ,Atkinson FM,James GC,et al. The pharmacokine tics of sildenafil after sing le intravenous and oral doses to mouse,rat and dog.Br J Pha rmacol,1996;42(2):2 67p
14 Muirhead AM,Pearson JG,Rance D,et al. Pharmacokine tics of sildenafil (Viagra TM),a selective cGMP PDE5 inhibitor after single oral doses in fasted and fed healthy volunteer s.Br J Phar-macol,1996;4 2(2):P 268
15 Boolell M,Gepi-Attee S,Ginge ll JC,et al. Sildenafil,a novel effective oral the rapy for male erectile dysfunction.Br J Uro,1996;7 8:257
16 Cappelleri JC,Rosen RC,Quirk F.VIAGRA TM (Sildenafil citrate)improve s quality of life in erectile dysfunction. American Psychological Association,Annual Meeting,August 1998
17 Morales A,Gingell C,Collins M,et al. Clinical safety of oral sildenafil citrate (viagra)in the
18 treatment of erectile dysfunction. Int JImpot Res,1998;1 0:6 9
18 Hartman U,Meuleman EJH,Cuzin B,et al. Sildenafil (Viagra T M):analysis of preferred doses in a european,6 month,double-blind,placebocont rolled,flex ible dose escalation study in patients with erectile dysfunction. Int J Impot Res,1998;10(suppl3):S 34
19 Giuliano F,Jardin A,Gingell CJ,et al. Slidenafil(VIAG RA TM),an oral treatment for erectile dysfunction:a 1-year,open-label ex tension study.Br J Urol,1997;80(2):93
20 Padma-Na than J,Monica S.A 24-week,fixed-dose study to assess the efficacy and safety of sildenafil (Viagra T M)in men with erectiledys function. J Uro l,1998;159(suppl):2 38 |
